(6,6-dimethyl-tetrahydro-pyran-2-yl)-acetic acid methyl ester | 489429-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (6,6-dimethyl-tetrahydro-pyran-2-yl)-acetic acid methyl ester
• 英文别名: methyl 2-(6,6-dimethyltetrahydropyran-2-yl)acetate；methyl 2-(6,6-dimethyloxan-2-yl)acetate
• CAS: 489429-37-0
• 化学式: C₁₀H₁₈O₃
• 分子量: 186.251
• InChiKey: DUAKGXNZXHKACY-UHFFFAOYSA-N

物化性质

• 沸点：
  227.7±13.0 °C(Predicted)
• 密度：
  0.962±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-氯-3-碘丙烷 、 (6,6-dimethyl-tetrahydro-pyran-2-yl)-acetic acid methyl ester 在 六甲基磷酰三胺 、 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.58h， 生成 methyl 5-chloro-2-(6,6-dimethyltetrahydropyran-2-yl)valerate
  参考文献：
  名称：

  MULTI-CYCLIC COMPOUNDS

  摘要：

  一种由化学式(I)表示的化合物或其药理学可接受的盐，其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团，Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团，X1代表双键或类似基团，Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团，对由Aβ引起的疾病具有治疗或预防作用。

  公开号：

  US20090062529A1
• 作为产物：
  描述：

  1-氯-3-甲基-2-丁烯 在 sodium tetrahydroborate 、 cerium(III) chloride 、 sodium iodide 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 14.0h， 生成 (6,6-dimethyl-tetrahydro-pyran-2-yl)-acetic acid methyl ester
  参考文献：
  名称：

  CeCl₃·7H₂O−NaI Catalyzed Hydrooxacyclization of Unsaturated 3-Hydroxy Esters

  摘要：

  [GRAPHICS]Cerium(III) chloride heptahydrate and sodium iodide in boiling acetonitrile promote cyclization of 3-hydroxyalkenoic acids esters giving 5-substituted tetrahydrofuranacetic acid esters and 6-substituted tetrahydropyranacetic acid esters in fair to good yield and with complete retention of the absolute configuration of the starting 3-hydroxy ester.

  DOI：

  10.1021/ol026955z

文献信息

• [EN] DIOXOLANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF HOMOHARRINGTONINE<br/>[FR] INTERMÉDIAIRE DE DIOXOLANONE UTILE DANS LA SYNTHÈSE DE L'HOMOHARRINGTONINE
  申请人：INDENA SPA

  公开号：WO2018019549A1

  公开（公告）日：2018-02-01

  The invention discloses 2-((2R,4R)-4-(4-(benzyloxy)-4-methylpent-2-yn-1-yl)-2-(tert-butyl)-5-oxo-1,3-dioxolan-4-yl)acetic acid of formula (XIX), a process for its preparation and processes for its conversion into enantiomerically pure (R)-2-(2-methoxy-2-oxoethyl)-6,6-dimethyltetrahydro-2H-pyran-2-carboxylic acid of formula (I), a molecule useful for the synthesis of Homoharringtonine.

  该发明公开了式（XIX）的2-((2R,4R)-4-(4-(苄氧基)-4-甲基戊-2-炔-1-基)-2-(叔丁基)-5-氧代-1,3-二氧杂环戊-4-基)乙酸，其制备方法以及将其转化为式（I）的对映纯(R)-2-(2-甲氧基-2-氧代乙基)-6,6-二甲基四氢-2H-吡喃-2-羧酸的方法，该分子可用于合成吉非替林。
• MULTI-CYCLIC COMPOUNDS
  申请人：KIMURA Teiji

  公开号：US20090062529A1

  公开（公告）日：2009-03-05

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  一种由化学式(I)表示的化合物或其药理学可接受的盐，其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团，Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团，X1代表双键或类似基团，Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团，对由Aβ引起的疾病具有治疗或预防作用。
• IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF
  申请人：KIMURA Teiji

  公开号：US20110065696A1

  公开（公告）日：2011-03-17

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  化合物的化学式为(I)或其药理学上可接受的盐，其中Ar1代表咪唑基团或类似基团，该基团可能被C1-6烷基取代，Ar2代表苯基或类似基团，该基团可能被C1-6烷氧基取代，X1代表双键或类似基团，Het代表三唑基团或类似基团，该基团可能被C1-6烷基或类似基团取代，可用作治疗或预防由Aβ引起的疾病的药物。
• Imidazoyl pyridine compounds and salts thereof
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US07935815B2

  公开（公告）日：2011-05-03

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  化合物的化学式为（I）或其药学上可接受的盐，其中Ar1代表咪唑基团或类似基团，可以用C1-6烷基基团取代，Ar2代表苯基团或类似基团，可以用C1-6烷氧基基团取代，X1代表双键或类似基团，Het代表三唑基团或类似基团，可以用C1-6烷基基团或类似基团取代，对由Aβ引起的疾病具有治疗或预防作用。
• Polycyclic compound
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2559693A1

  公开（公告）日：2013-02-20

  Disclosed is a compound represented by the formula (I-1): or a pharmacologically acceptable salt thereof, which is effective as a therapeutic or prophylactic agent for a disease induced by Aβ, wherein X1 represents -CH=CH- and Het represents a group which may be substituted with 1 to 3 substituents selected from substituents group A1 and is represented by one of the following formulas:

  本发明公开了一种由式（I-1）表示的化合物： 或其药理上可接受的盐，可有效治疗或预防由 Aβ 诱导的疾病，其中 X1 代表-CH=CH-，Het 代表可被 1 至 3 个选自取代基 A1 的取代基取代的基团，并由下式之一表示：